White Paper: Developing Antimicrobial Drugs for Resistant Pathogens, Narrow-Spectrum Indications, and Unmet Needs.

Area of Science:

• Infectious Diseases
• Clinical Trial Design
• Antimicrobial Resistance

Background:

• A critical need exists for novel antibacterial agents to combat drug-resistant bacteria, particularly gram-negative bacilli, which cause significant morbidity and mortality.
• Traditional clinical trial designs, often focused on single infection sites, may not be optimal or feasible for studying new antibacterial agents against resistant pathogens.

Purpose of the Study:

• To advocate for a novel and pragmatic approach to antibacterial drug development.
• To present feasible clinical trial designs for antibacterial agents targeting drug-resistant bacteria.

Main Methods:

• Review and consensus-building among multiple stakeholders on pathways for antimicrobial development.
• Proposal of novel, organism-specific clinical trial designs.

Main Results:

• The proposed designs aim to facilitate the timely conduct of clinical trials for narrow-spectrum antibacterial agents.
• These designs are intended to enable the approval of critically needed new antibacterial agents.

Conclusions:

• Novel and pragmatic clinical trial designs are essential for advancing the development of antibacterial agents against resistant gram-negative bacilli.
• The proposed organism-specific trial designs offer a feasible path forward for drug approval and addressing public health challenges posed by antimicrobial resistance.